SCHEMBL1810358

SCHEMBL1810358

O=C(O)Cc1csc(SCC(=O)NCC2CN(Cc3cccc4cc(F)ccc34)CCO2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
DRD4 P21917 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 1/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
ACKR3 P25106 1/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RXFP1 Q9HBX9 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1807374 0.94 ALDH1A1 (0.41) ALDH1A1DRD4L3MBTL1KMT2ATDP1
SCHEMBL1809701 0.91 HPGD (0.44) ALDH1A1DRD4L3MBTL1KMT2ATDP1
SCHEMBL1809022 0.89 ALDH1A1 (0.44) ALDH1A1DRD4L3MBTL1KMT2ATDP1
SCHEMBL1809030 0.89 ALDH1A1 (0.44) ALDH1A1DRD4L3MBTL1KMT2ATDP1
SCHEMBL1805878 0.88 ALDH1A1 (0.51) ALDH1A1DRD4KMT2ATDP1MEN1
SCHEMBL1805873 0.88 ALDH1A1 (0.51) ALDH1A1DRD4KMT2ATDP1MEN1
SCHEMBL12625660 0.87 ALDH1A1 (0.47) ALDH1A1DRD4KMT2AMEN1CYP1A2
SCHEMBL1808494 0.86 ALDH1A1 (0.47) ALDH1A1L3MBTL1KMT2ATDP1NPC1
SCHEMBL1808489 0.86 ALDH1A1 (0.47) ALDH1A1L3MBTL1KMT2ATDP1NPC1
SCHEMBL1807940 0.86 ALDH1A1 (0.52) ALDH1A1DRD4KMT2ATDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 ALDH1A1 2661/4885DRD4 768/4885L3MBTL1 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.